Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Long-term ibrutinib outcomes vs. prior regimens: pooled analysis in R/R MCL

Simon Rule, MD, Plymouth University, Plymouth, UK, outlines data from a pooled analysis of ibrutinib in relapsed/refractory (R/R) mantle cell lymphoma (MCL) with extended follow-up up to 7.5 years and a comparison of outcomes with ibrutinib versus the prior regimens. Prof. Rule considers that the key message from this analysis is that ibrutinib should be used at first relapsed, even in patients that get the best response to chemotherapy. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.